loading
Schlusskurs vom Vortag:
$12.78
Offen:
$12.61
24-Stunden-Volumen:
72,010
Relative Volume:
0.06
Marktkapitalisierung:
$969.38M
Einnahmen:
$54.55M
Nettoeinkommen (Verlust:
$-193.57M
KGV:
-4.3678
EPS:
-2.89
Netto-Cashflow:
$-181.86M
1W Leistung:
+14.11%
1M Leistung:
+36.96%
6M Leistung:
+9.76%
1J Leistung:
-48.52%
1-Tages-Spanne:
Value
$12.46
$12.78
1-Wochen-Bereich:
Value
$11.19
$13.23
52-Wochen-Spanne:
Value
$8.18
$29.56

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name
Firmenname
Nurix Therapeutics Inc
Name
Telefon
(415) 660-5320
Name
Adresse
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Name
Mitarbeiter
286
Name
Twitter
Name
Nächster Verdiensttermin
2025-10-09
Name
Neueste SEC-Einreichungen
Name
NRIX's Discussions on Twitter

Vergleichen Sie NRIX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NRIX
Nurix Therapeutics Inc
12.68 1.30B 54.55M -193.57M -181.86M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
419.32 107.66B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
650.66 68.74B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
442.86 58.93B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
815.13 50.51B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
191.63 41.29B 398.11M -1.03B -868.57M -5.7032

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-21 Eingeleitet Mizuho Outperform
2025-03-17 Eingeleitet Leerink Partners Market Perform
2024-12-10 Eingeleitet BTIG Research Buy
2024-12-06 Eingeleitet BMO Capital Markets Outperform
2024-10-24 Eingeleitet UBS Buy
2024-10-11 Eingeleitet Jefferies Buy
2024-09-06 Fortgesetzt Robert W. Baird Outperform
2024-07-31 Eingeleitet Truist Buy
2023-06-26 Fortgesetzt Oppenheimer Outperform
2023-03-09 Eingeleitet Barclays Overweight
2023-02-28 Eingeleitet Oppenheimer Outperform
2022-10-11 Eingeleitet Morgan Stanley Equal-Weight
2022-05-31 Hochstufung Wells Fargo Equal Weight → Overweight
2022-02-10 Eingeleitet Wells Fargo Equal Weight
2021-12-29 Eingeleitet H.C. Wainwright Buy
2021-10-14 Eingeleitet SVB Leerink Outperform
2021-06-04 Fortgesetzt Robert W. Baird Outperform
2021-04-30 Fortgesetzt Piper Sandler Overweight
2021-04-30 Eingeleitet RBC Capital Mkts Outperform
2021-04-14 Eingeleitet Berenberg Buy
2020-11-19 Eingeleitet Robert W. Baird Outperform
2020-08-18 Eingeleitet JP Morgan Overweight
2020-08-18 Eingeleitet Needham Buy
2020-08-18 Eingeleitet Piper Sandler Overweight
2020-08-18 Eingeleitet Stifel Buy
Alle ansehen

Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten

pulisher
05:20 AM

How institutional ownership impacts Nurix Therapeutics Inc. stock2025 Momentum Check & Safe Capital Preservation Plans - newser.com

05:20 AM
pulisher
04:45 AM

Full technical analysis of Nurix Therapeutics Inc. stockJuly 2025 Earnings & Long Hold Capital Preservation Tips - newser.com

04:45 AM
pulisher
04:18 AM

How moving averages guide Nurix Therapeutics Inc. tradingMarket Performance Report & Daily Risk Controlled Trade Plans - newser.com

04:18 AM
pulisher
01:49 AM

Will Nurix Therapeutics Inc. stock go up soonPortfolio Value Summary & Consistent Profit Trading Strategies - newser.com

01:49 AM
pulisher
01:47 AM

Nurix Therapeutics CFO van Houte sells $40k in shares By Investing.com - Investing.com UK

01:47 AM
pulisher
01:34 AM

Will Nurix Therapeutics Inc. stock deliver consistent dividendsQuarterly Trade Review & Risk Controlled Daily Plans - newser.com

01:34 AM
pulisher
01:05 AM

Can Nurix Therapeutics Inc. recover in the next quarterEarnings Summary Report & Daily Momentum Trading Reports - newser.com

01:05 AM
pulisher
Oct 30, 2025

Nurix Therapeutics CLO ring sells shares for $46,631 By Investing.com - Investing.com Canada

Oct 30, 2025
pulisher
Oct 30, 2025

Nurix therapeutics CSO Hansen sells $52k in shares By Investing.com - Investing.com Philippines

Oct 30, 2025
pulisher
Oct 30, 2025

Nurix Therapeutics CFO van Houte sells $40k in shares - Investing.com

Oct 30, 2025
pulisher
Oct 30, 2025

Nurix therapeutics CSO Hansen sells $52k in shares - Investing.com

Oct 30, 2025
pulisher
Oct 30, 2025

Nurix Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Oct 30, 2025
pulisher
Oct 30, 2025

Nurix Therapeutics (Nasdaq: NRIX) to join Stifel Nov 13 and Jefferies Nov 19 webcasts - Stock Titan

Oct 30, 2025
pulisher
Oct 30, 2025

Is Nurix Therapeutics Inc. building a consolidation baseInflation Watch & High Return Trade Guides - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

HC Wainwright Cuts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $28.00 - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Visual trend scoring systems applied to Nurix Therapeutics Inc.July 2025 Retail & Technical Confirmation Trade Alerts - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

AlphaQuest LLC Boosts Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Nurix Therapeutics Inc. stock daily chart insightsJuly 2025 Gainers & Technical Entry and Exit Tips - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

What technical charts say about Nurix Therapeutics Inc. stockTrade Risk Report & Low Risk High Reward Ideas - newser.com

Oct 29, 2025
pulisher
Oct 28, 2025

Nurix Therapeutics (NASDAQ:NRIX) Trading 7.7% HigherHere's Why - MarketBeat

Oct 28, 2025
pulisher
Oct 28, 2025

HC Wainwright & Co. Maintains Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq

Oct 28, 2025
pulisher
Oct 28, 2025

Nurix stock price target lowered to $28 at H.C. Wainwright on trial updates - Investing.com UK

Oct 28, 2025
pulisher
Oct 28, 2025

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 34% Price Boost Is Out Of Tune With Revenues - 富途牛牛

Oct 28, 2025
pulisher
Oct 28, 2025

Will Nurix Therapeutics Inc. bounce back from current supportWeekly Risk Summary & AI Optimized Trading Strategy Guides - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Applying chart zones and confluence areas to Nurix Therapeutics Inc.Weekly Trade Report & Long-Term Growth Stock Strategies - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

Nurix Therapeutics closes $250 million stock offering By Investing.com - Investing.com Philippines

Oct 27, 2025
pulisher
Oct 27, 2025

Why Nurix Therapeutics Inc. stock is seen as undervaluedQuarterly Trade Review & Safe Swing Trade Setup Alerts - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

Nurix Therapeutics’ NX-1607 Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Nurix Therapeutics Advances NX-5948 Study in B-cell Malignancies - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Nurix Therapeutics’ NX-2127 Study: A Potential Game-Changer in B-cell Malignancy Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Nurix Therapeutics’ NX-5948 Study: A Potential Game-Changer in Drug Delivery - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Fenwick Represents Nurix Therapeutics in its $250M Registered Common Stock Offering - fenwick.com

Oct 27, 2025
pulisher
Oct 27, 2025

Nurix Therapeutics closes $250 million stock offering - Investing.com

Oct 27, 2025
pulisher
Oct 27, 2025

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock - Investing News Network

Oct 27, 2025
pulisher
Oct 27, 2025

Nurix (NASDAQ: NRIX) closes 24.5M-share offering at $10.21 for CLL, autoimmune - Stock Titan

Oct 27, 2025
pulisher
Oct 27, 2025

Leerink Partnrs Has Bullish Outlook for NRIX FY2025 Earnings - MarketBeat

Oct 27, 2025
pulisher
Oct 27, 2025

Can Nurix Therapeutics Inc. stock hit record highs againJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com

Oct 27, 2025

Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Nurix Therapeutics Inc-Aktie (NRIX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
van Houte Hans
Chief Financial Officer
Oct 30 '25
Sale
12.80
3,130
40,054
43,876
Ring Christine
Chief Legal Officer
Oct 30 '25
Option Exercise
0.00
10,532
0
54,541
Ring Christine
Chief Legal Officer
Oct 30 '25
Sale
12.80
3,644
46,631
50,897
Hansen Gwenn
Chief Scientific Officer
Oct 30 '25
Option Exercise
0.00
11,815
0
80,838
Hansen Gwenn
Chief Scientific Officer
Oct 30 '25
Sale
12.80
4,087
52,300
76,751
GREGORY JULIA P
Director
Sep 17 '25
Option Exercise
1.86
10,750
19,995
10,750
van Houte Hans
Chief Financial Officer
Aug 01 '25
Sale
11.03
5,402
59,598
35,512
$37.05
price up icon 0.11%
$92.39
price up icon 0.00%
$28.43
price down icon 0.84%
$104.11
price down icon 0.54%
biotechnology ONC
$310.99
price up icon 0.50%
$191.50
price down icon 0.32%
Kapitalisierung:     |  Volumen (24h):